BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37698635)

  • 1. Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".
    Song Y; Xu T
    World J Urol; 2023 Nov; 41(11):3379-3380. PubMed ID: 37698635
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
    Del Giudice F; Belladelli F; Glover F; Basran S; Li S; Mulloy E; Pradere B; Soria F; Krajewski W; Nair R; Muncey W; Seranio N; Eisenberg ML
    World J Urol; 2023 Oct; 41(10):2783-2791. PubMed ID: 37548746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
    Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
    J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign Prostatic Hyperplasia.
    Langan RC
    Prim Care; 2019 Jun; 46(2):223-232. PubMed ID: 31030823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [REVIEW OF CLINICAL STUDIES ON COMBINATION THERAPY OF 5α-REDUCTASE INHIBITORS AND α1-BLOCKERS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA].
    Spivak LG; Lokshin KL; Vinarov AZ
    Urologiia; 2015; (4):125-33. PubMed ID: 26665780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
    Zhang H; Frendl DM; Wang Z; Olumi AF
    J Urol; 2020 Aug; 204(2):325-331. PubMed ID: 32167867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
    Zhang J; Latour CD; Olawore O; Pate V; Friedlander DF; Stürmer T; Jonsson Funk M; Jensen BC
    JAMA Netw Open; 2023 Nov; 6(11):e2343299. PubMed ID: 37962887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
    Robinson D; Garmo H; Holmberg L; Stattin P
    Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
    Kang D; Hu C; Fu Y; Wang D
    Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination therapy for benign prostatic hyperplasia in the light of clinical guidelines].
    Vinarov AZ; Spivak LG; Mironov AV
    Urologiia; 2017 Sep; (4):120-128. PubMed ID: 28952704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
    Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
    BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
    Hagberg KW; Divan HA; Nickel JC; Jick SS
    Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of recent trends in treatment patterns among men with benign prostatic hyperplasia.
    Kruep EJ; Goodwin BB; Chaudhari S
    Am J Mens Health; 2013 May; 7(3):214-9. PubMed ID: 23221685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
    Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
    Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
    DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
    Lim SY; Laengvejkal P; Panikkath R; Nugent K
    Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current opportunities of pharmacotherapy of prostatic adenoma].
    Apolikhin OI; Sivkov AV; Beshliev DA; Abdullin II
    Urologiia; 2010; (2):54-9. PubMed ID: 20967996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.